These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34085289)

  • 1. Value-based drug pricing in the Biden era: Opportunities and prospects.
    Neumann PJ; Ollendorf DA; Cohen JT
    Health Serv Res; 2021 Dec; 56(6):1093-1099. PubMed ID: 34085289
    [No Abstract]   [Full Text] [Related]  

  • 2. The scandal of generic drug pricing: drug regulation policies need review.
    Meeran K; Choudhury SM; Wass J
    BMJ; 2017 Feb; 356():j947. PubMed ID: 28232321
    [No Abstract]   [Full Text] [Related]  

  • 3. Value-Based Pricing for Drugs: Theme and Variations.
    Kaltenboeck A; Bach PB
    JAMA; 2018 Jun; 319(21):2165-2166. PubMed ID: 29710320
    [No Abstract]   [Full Text] [Related]  

  • 4. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs.
    Cahn LJ
    Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372
    [No Abstract]   [Full Text] [Related]  

  • 5. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs.
    Chakradhar S; Khamsi R
    Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215
    [No Abstract]   [Full Text] [Related]  

  • 7. The Impact of Off-Patent Drug Acquisitions on Prices.
    Gupta R; Henkel A; Forman HP; Ross JS
    J Gen Intern Med; 2018 Jul; 33(7):1007-1009. PubMed ID: 29687433
    [No Abstract]   [Full Text] [Related]  

  • 8. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indication-specific Drug Pricing - Simple in Theory, Complex in Reality.
    Kwon S
    Manag Care; 2018 May; 27(5):23-25. PubMed ID: 29763404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brand-name versus generic.
    Copeland KR; Boccuzzi SJ
    Health Aff (Millwood); 2007; 26(4):1198-9; author reply 1199. PubMed ID: 17630468
    [No Abstract]   [Full Text] [Related]  

  • 11. Generic drugs: are they the future for affordable medicine?
    The Lancet Oncology
    Lancet Oncol; 2018 Feb; 19(2):149. PubMed ID: 29413460
    [No Abstract]   [Full Text] [Related]  

  • 12. Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem.
    Hollis A; Grootendorst P
    Healthc Policy; 2015 Aug; 11(1):10-4. PubMed ID: 26571465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who Needs XR, LA, SR, XL, ER, or CR?
    Curtiss FR
    J Manag Care Pharm; 2005; 11(9):772-3, 775-6. PubMed ID: 16300421
    [No Abstract]   [Full Text] [Related]  

  • 14. Undermining Value-Based Purchasing - Lessons from the Pharmaceutical Industry.
    Dafny LS; Ody CJ; Schmitt MA
    N Engl J Med; 2016 Nov; 375(21):2013-2015. PubMed ID: 27732125
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new drug war.
    Sherrid P
    US News World Rep; 2002 Dec; 133(21):41. PubMed ID: 12503485
    [No Abstract]   [Full Text] [Related]  

  • 17. Addressing Generic-Drug Market Failures - The Case for Establishing a Nonprofit Manufacturer.
    Liljenquist D; Bai G; Anderson GF
    N Engl J Med; 2018 May; 378(20):1857-1859. PubMed ID: 29768140
    [No Abstract]   [Full Text] [Related]  

  • 18. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-18. PubMed ID: 20213921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.